Ratios in Focus: Analyzing Immunome Inc (IMNM)’s Price-to-Cash and Price-to-Free Cash Flow

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, Immunome Inc (NASDAQ: IMNM) closed at $12.58 down -5.27% from its previous closing price of $13.28. In other words, the price has decreased by -$5.27 from its previous closing price. On the day, 1.33 million shares were traded. IMNM stock price reached its highest trading level at $13.29 during the session, while it also had its lowest trading level at $12.27.


For a deeper understanding of Immunome Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.18 and its Current Ratio is at 10.18. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on May 31, 2024, initiated with a Overweight rating and assigned the stock a target price of $27.

On April 30, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $24.

On April 15, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $35.Guggenheim initiated its Buy rating on April 15, 2024, with a $35 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 21 ’24 when SIEGALL CLAY B bought 20,434 shares for $13.78 per share. The transaction valued at 281,548 led to the insider holds 419,636 shares of the business.

BIENAIME JEAN JACQUES bought 2,000 shares of IMNM for $27,140 on May 21 ’24. The Director now owns 9,615 shares after completing the transaction at $13.57 per share. On May 20 ’24, another insider, SIEGALL CLAY B, who serves as the President and CEO of the company, bought 79,566 shares for $13.91 each. As a result, the insider paid 1,106,524 and bolstered with 399,202 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 796386944 and an Enterprise Value of 446327360. For the stock, the TTM Price-to-Sale (P/S) ratio is 59.50 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 35.191 whereas that against EBITDA is -10.125.

Stock Price History:

The Beta on a monthly basis for IMNM is 1.79, which has changed by 1.2585278 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $30.96, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is -18.85%, while the 200-Day Moving Average is calculated to be -10.41%.

Shares Statistics:

For the past three months, IMNM has traded an average of 800.08K shares per day and 845930 over the past ten days. A total of 59.97M shares are outstanding, with a floating share count of 48.99M. Insiders hold about 18.31% of the company’s shares, while institutions hold 60.05% stake in the company. Shares short for IMNM as of 1715731200 were 6123723 with a Short Ratio of 10.09, compared to 1713139200 on 3747870. Therefore, it implies a Short% of Shares Outstanding of 6123723 and a Short% of Float of 10.8.

Earnings Estimates

The stock of Immunome Inc (IMNM) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.39 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.57, while EPS last year was -$0.35. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.21 and low estimates of -$0.64.

Analysts are recommending an EPS of between -$2.93 and -$3.87 for the fiscal current year, implying an average EPS of -$3.6. EPS for the following year is -$2.63, with 6.0 analysts recommending between -$1.92 and -$3.88.

Revenue Estimates

A total of 6 analysts have provided revenue estimates for IMNM’s current fiscal year. The highest revenue estimate was $16M, while the lowest revenue estimate was $1M, resulting in an average revenue estimate of $7M. In the same quarter a year ago, actual revenue was $14.02M

Most Popular